Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis

• Egile Nagusiak: Vivaswath S. Ayyar (Egilea), Jong Bong Lee (Egilea), Weirong Wang (Egilea), Meghan Pryor (Egilea), Yanli Zhuang (Egilea), Thomas Wilde (Egilea), An Vermeulen (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The pharmacologic effect(s) of biotherapeutics directed against soluble targets are driven by the magnitude and duration of free target suppression at the tissue site(s) of action. Interleukin (IL)-17A is an inflammatory cytokine that plays a key role in the pathogenesis of psoriasis. In this work,...